Key result
Enalapril slowed the progression of chronic nephropathy compared to conventional therapy, with a median GFR decline of -0.20 vs -0.31 mL/min/1.73 m2/month (P<0.05).
Why the study?
Does enalapril reduce the progression of chronic nephropathy in patients with moderate to severe chronic renal failure compared to conventional antihypertensive treatment?
RCT (n=70)
Open-label
Does enalapril reduce the progression of chronic nephropathy in patients with moderate to severe chronic renal failure compared to conventional antihypertensive treatment?
Absolute Event Rate: -0.2% vs -0.31%
p-value: p=<0.05
Enalapril significantly slows the decline of glomerular filtration rate in patients with moderate to severe chronic nephropathy compared to conventional antihypertensive therapy.
No takes yet. Share an insight, caveat, or question.
Supports enalapril to slow GFR decline in moderate-severe chronic nephropathy; confirms ACE inhibitor benefit on CKD progression.
Kamper et al. (1992) conducted an RCT in Chronic renal failure (n=70). Enalapril vs. Conventional antihypertensive treatment was evaluated on Median decline in GFR (mL/min/1.73 m2/month) (p=<0.05). Enalapril slowed the progression of chronic nephropathy compared to conventional therapy, with a median GFR decline of -0.20 vs -0.31 mL/min/1.73 m2/month (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: